2-((1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((S,E)-3-hydroxyoct-1-enyl)-1H-cyclopenta[b]naphthalen-5-yloxy)acetic acid | 81845-88-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-((1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((S,E)-3-hydroxyoct-1-enyl)-1H-cyclopenta[b]naphthalen-5-yloxy)acetic acid
• 英文别名: 2-((1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((3S,1E)-3-hydroxyoct-1-enyl)-1H-cyclopenta[b]naphthalen-5-yloxy)acetic acid；2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(E,3S)-3-hydroxyoct-1-enyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
• CAS: 81845-88-7
• 化学式: C₂₃H₃₂O₅
• 分子量: 388.504
• InChiKey: ILZGLZKCNKQDPW-YCIAMDESSA-N

物化性质

• 沸点：
  571.1±50.0 °C(Predicted)
• 密度：
  1.218±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-((1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((S,E)-3-hydroxyoct-1-enyl)-1H-cyclopenta[b]naphthalen-5-yloxy)acetic acid 以88的产率得到曲前列尼尔
  参考文献：
  名称：

  Intermediates for the synthesis of benzindene prostaglandins and preparations thereof

  摘要：

  本发明提供了用于制备对制备苯并二烯前列腺素有用的光学活性环戊酮1的新工艺，同时提供了制备苯并二烯前列腺素的新工艺和苯并二烯前列腺素的新中间体。

  公开号：

  EP2581361A1
• 作为产物：
  描述：

  (1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((S,E)-3-hydroxyoct-1-enyl)-1H-cyclopenta[b]naphthalen-5-yl acetate 在 甲醇 、 sodium hydroxide 作用下， 反应 1.0h， 以82%的产率得到2-((1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((S,E)-3-hydroxyoct-1-enyl)-1H-cyclopenta[b]naphthalen-5-yloxy)acetic acid
  参考文献：
  名称：

  Intermediates for the synthesis of benzindene prostaglandins and preparations thereof

  摘要：

  公开号：

  EP2581361B1

文献信息

• INTERMEDIATES FOR THE SYNTHESIS OF BENZINDENE PROSTAGLANDINS AND PREPARATIONS THEREOF
  申请人：WEI Shih-Yi

  公开号：US20130053581A1

  公开（公告）日：2013-02-28

  Novel processes for preparing optically active cyclopentanones 1 which are useful for the preparation of benzindene Prostaglandins and novel cyclopentanones are provided. The invention also provides novel processes of preparing benzindene Prostaglandins and novel intermediates for benzindene Prostaglandins.

  提供了用于制备对制备苯二烯前列腺素有用的光学活性环戊酮的新工艺。该发明还提供了制备苯二烯前列腺素和苯二烯前列腺素中间体的新工艺。
• Synthesis of binzindene prostaglandins: a novel potent class of stable prostacyclin analogs
  作者：Paul A. Aristoff、Allen W. Harrison

  DOI：10.1016/s0040-4039(00)87262-7

  日期：1982.1

  The phenols , , and , produced with remarkable regioselectivity by the cyclization of compounds and , have been converted to the benzindene prostaglandin analogs , , and , respectively. Compounds and are potent prostacyclin mimics.

  酚，和与由化合物的环化显着的区域选择性产生和，已转换为所述苯并茚前列腺素类似物，和分别。化合物和都是有效的前列环素模拟物。
• Composition and process
  申请人：The Upjohn Company

  公开号：US04306075A1

  公开（公告）日：1981-12-15

  The present specification provides novel analogs of carbacyclin (CBA.sub.2), 6a-carba-prostacyclin (6a-carba-PGI.sub.2), which have pronounced prostacyclin-like pharmacological activity, e.g., as platelet antiaggregatory agents. Specifically the novel chemical analogs of CBA.sub.2 are those substituted by fluoro (C-5), alkyl (C-9), interphenylene (C-5), and methano (C-6a,9). Further provided are benzindene analogs of CBA.sub.2 and substituted forms thereof, i.e., 9-deoxy-2',9-methano (or 2',9-metheno)-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylene)-PGF.sub.1 compounds. Also provided are a variety of novel chemical intermediates, e.g., substituted bicyclo[3.3.0]octane intermediates, and chemical process utilizing such intermediates which are useful in the preparation of the novel CBA.sub.2 analogs.

  本规范提供了新型的卡巴环素(CBA.sub.2)、6a-卡巴-前列环素(6a-carBA-PGI.sub.2)的类似物，这些类似物具有明显的前列环素类药理活性，例如作为血小板抗凝剂。具体而言，CBA.sub.2的新型化学类似物是那些被氟(C-5)、烷基(C-9)、互芳烃(C-5)和甲基(C-6a,9)取代的物质。此外，还提供了CBA.sub.2的苯并二烯类似物及其取代形式，即9-去氧-2',9-甲基(或2',9-甲烯)-3-氧杂-4,5,6-三脱-3,7-(1',3'-互芳基)-PGF.sub.1化合物。还提供了各种新型的化学中间体，例如取代的双环[3.3.0]辛烷中间体，以及利用这些中间体的化学过程，这些中间体在新型CBA.sub.2类似物的制备中非常有用。
• J. Am. Chem. Soc. 1973, 95, 6462-6463
  作者：

  DOI：——

  日期：——
• Tetrahedron Lett. 1982, 23, 2067-2070
  作者：

  DOI：——

  日期：——